相关实验视频

Updated: Jun 23, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

向FTO通过抑制ERBB3和TUBB4A表达来抑制肝细胞癌

Lingli Jiang¹, Rui Liang¹, Qing Luo¹

¹College of Bioengineering, Key Laboratory of Biorheological Science and Technology, Ministry of Education, Chongqing University, Chongqing 400044, China.

Biochemical pharmacology

|June 21, 2024

概括

脂肪量和与肥胖相关的蛋白质 (FTO) 是肝癌的关键驱动因素. 用FB23-2抑制FTO通过向ERBB3和TUBB4A来抑制肝细胞癌 (HCC) 的进展,显示出新的癌症疗法的潜力.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生物化学

背景情况:

脂肪质量和肥胖相关蛋白 (FTO) 是一种N6-甲基氨酸 (m6A) 脱甲基酶,涉及各种癌症.
FTO的致癌作用表明它是恶性瘤中潜在的治疗点.

研究的目的:

研究FTO在肝细胞癌 (HCC) 进展中的作用.
评估FTO抑制作为HCC治疗策略的疗效.

主要方法:

在HCC患者中评估FTO表达.
在HCC细胞系和小鼠模型中利用了FTO的遗传枯竭和药理抑制 (FB23/FB23-2).
研究了涉及m6A修饰,ERBB3,TUBB4A和Akt-mTOR信号的下游分子机制.

主要成果:

在HCC患者中,FTO的表达很高,其耗尽会减轻小鼠的HCC进展.
通过FB23/FB23-2抑制FTO的药理抑制抑制了HCC细胞的增殖,迁移和瘤性.
FB23-2增加了ERBB3和TUBB4AmRNA的m6A水平,导致ERBB3表达的减少和Akt-mTOR通路的抑制.
FB23-2 破坏了管细胞骨的稳定性,而 TUBB4A 的过度表达则挽救了 HCC 细胞迁移.

结论:

通过促进细胞增殖和迁移,FTO在HCC中发挥着关键的致癌作用.
FTO抑制,特别是FB23-2的抑制,代表了肝细胞癌的有前途的治疗策略.

关键词:

在ERBB3中,ERBB3是ERBB3中的一个.在FB23-2中,FB23-2是在FTO FTO FTO 肝细胞癌 (HCC) 是一种肝细胞癌.N6 - 甲基氨酸 (m6A) 的使用.管道4A 管道4A 管道

更多相关视频

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines

Published on: April 18, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...